In a regulatory 8-K filing, the company states: “On August 15, 2023, United Therapeutics (UTHR) was issued patent number 11,723,887, the claims of which generally cover the manufacture of treprostinil salts. This patent belongs to the same patent family as U.S. patents 9,593,066, 9,604,901, and 8,497,393, each of which has been subject to previous litigation, and covers the same basic method of manufacturing treprostinil. Liquidia Corporation, (LQDA) is evaluating the claims of the patent and intends to aggressively defend the ability of patients to access the Company’s products.” Shares of Liquidia are down 6.6% in pre-market trading at $6.50 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LQDA:
- Liquidia management to meet virtually with BTIG
- Liquidia reports Q2 EPS (36c), consensus (16c)
- Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- LQDA Upcoming Earnings Report: What to Expect?
- Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023